ReviewJournal of mood and anxiety disorders2024
The state of anxiety treatments for adolescents and adults down syndrome: Results from a scoping rapid review.
Review in Journal of mood and anxiety disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adolescents and adults with Down syndrome are noted to display symptoms consistent with various anxiety disorders. While evidenced-based practices, including psychotherapies and psychopharmacology, exist and effectively treat anxiety in neurotypical populations, less is known about anxiety treatments for persons with Down syndrome. A scoping rapid review was conducted in April 2023 to determine what treatments are being used to target anxiety in adolescents and adults with Down syndrome, the quality of those treatments, and their alignment with current evidence-based practices. A total of eleven articles, primarily single case or case series, published between 1981 and 2022 were identified targeting adolescents and adults with Down syndrome diagnosed with specific phobias, selective mutism, generalized anxiety disorder, agoraphobia with panic, and non-specific anxiety symptoms. Interventions used most often aligned with evidence-based anxiety treatment guidelines and included psychotherapy, complementary and alternative medicine, and psychopharmacology. While most studies reported positive treatment responses showing reductions in anxiety symptoms post-treatment, the quality and generalizability of the studies was primarily poor. More rigorous research evaluating the effects of treatment for anxiety symptoms in the DS population are needed to develop guidelines to address anxiety disorders in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.